UnitedHealth Group (UNH) Delivers Strong Q3 Beat with Margin Gains and Raised Guidance
Key Takeaways
- UnitedHealth reported third quarter 2026 revenue of $112.7 billion and adjusted earnings per share (EPS) of $4.69, beating the analyst consensus of roughly $4.14.
- The medical care ratio (MCR), the share of premium revenue paid out for medical claims, improved to 88.4% from 89.9% a year earlier and came in below expectations.
- Management raised full-year 2026 adjusted EPS guidance to at least $20.50, up from a prior range of $19.50 to $20.00 — its third increase this year.
- The core insurance arm, UnitedHealthcare, lifted its operating margin to 3.3%, while the Optum Health unit swung to operating earnings of $735 million from $41 million a year ago.
- Despite the beat, shares closed down 0.20% at $377.76, suggesting much of the positive news was already priced in.
Earnings Context and Why It Matters
As the largest U.S. health insurer, UnitedHealth Group (UNH) acts as a bellwether for the managed care sector, so its results carry significant weight for investors following healthcare trends. The company has been executing a turnaround under CEO Stephen Hemsley, who returned to the role in 2025 after earlier challenges reduced substantial market value. Efforts have focused on exiting unprofitable areas, reducing exposure to low-margin value-based care, and tightening medical cost controls. This quarter provides insight into whether those steps are producing lasting margin improvement, with potential effects on peers such as Humana, CVS Health, and Centene.
Reported Results
In the third quarter of 2026, UnitedHealth recorded revenue of $112.7 billion, down slightly from $113.2 billion a year ago yet above the consensus estimate of about $111.3 billion. Adjusted EPS reached $4.69, well above the $4.14 expected by analysts and higher than $2.92 in the same period last year. On a GAAP basis, net income totaled $4.11 billion, or $4.56 per share, compared with $2.35 billion, or $2.59 per share, in the prior year.
The medical care ratio stood out, declining to 88.4% from 89.9% a year earlier and below the roughly 89.7% that analysts had modeled. The company credited better medical cost management, changes in benefit design, pricing discipline, and improvements in care delivery, along with $610 million in favorable prior-period reserve development related to 2026 service dates.
By segment, UnitedHealthcare produced $86.3 billion in revenue and $2.8 billion in operating earnings, raising its operating margin to 3.3% from 2.1%. Optum contributed $66.9 billion in revenue and $3.7 billion in operating earnings. Optum Health, previously a drag on results, reported operating earnings of $735 million versus $41 million a year ago, even with revenue down 10% after the company reduced activity in markets lacking sufficient scale.
Market Reaction and Investor Sentiment
Shares of UnitedHealth rose in premarket trading but finished the day down 0.20% at $377.76, close to the nearly flat performance of the S&P 500. Analysts observed that the beat and guidance increase had been largely anticipated after earlier outlook raises. Cantor Fitzgerald maintained an Overweight rating, noting the muted response reflected news that was already anticipated. The limited movement indicates investors are shifting focus to whether the improved medical cost trends can hold into 2027 and beyond.
Forward Outlook and Key Factors to Monitor
The updated full-year 2026 guidance of at least $20.50 in adjusted EPS reflects management’s view that the turnaround remains on track. Executives suggested on the call that the lower end of the long-term 13%–16% growth range represents a reasonable starting point for 2027 earnings, pointing to potential upside versus current consensus estimates.
Several elements will influence upcoming results. Medical cost trends continue to run above historical norms, with ongoing pressure from specialty pharmacy and acute care intensity in commercial lines. The Medicare Advantage enrollment period and 2027 Stars ratings, where at least 69% of members are in 4+ Star plans, will provide signals on membership trends and reimbursement quality.
Optum Health is expected to see a seasonally softer fourth quarter while investments continue in technology, AI, and workflow improvements. Medicaid margins are still negative, with 2026 viewed as a trough year before state funding aligns better with costs.
Capital returns remain active, with $5.0 billion in share repurchases and $6.2 billion in dividends paid year-to-date and a debt-to-capital ratio of 41.7% moving toward a 40% target. Investors will track whether cost discipline and business-mix shifts support ongoing margin expansion while maintaining the growth needed for longer-term objectives.
Using Tickeron’s AI Screener in My Research
When analyzing earnings movers like this one, I often turn to Tickeron’s AI Screener to quickly compare UnitedHealth with other healthcare names. The tool lets me apply filters for industry, performance metrics, and technical signals, helping surface ideas more efficiently than manual checks alone. It has become a regular part of how I build and refine watchlists across sectors.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
UNH's Indicator enters downward trend
The Aroon Indicator for UNH entered a downward trend on October 12, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 123 similar instances where the Aroon Indicator formed such a pattern. In 82 of the 123 cases the stock moved lower. This puts the odds of a downward move at 67%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 63 cases where UNH's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where UNH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where UNH's RSI Indicator exited the oversold zone, 26 of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Momentum Indicator moved above the 0 level on October 09, 2026. You may want to consider a long position or call options on UNH as a result. In 44 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for UNH just turned positive on October 05, 2026. Looking at past instances where UNH's MACD turned positive, the stock continued to rise in 25 of 46 cases over the following month. The odds of a continued upward trend are 54%.
Following a +3.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where UNH advanced for three days, in 187 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
UNH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.445) is normal, around the industry mean (3.247). P/E Ratio (24.282) is within average values for comparable stocks, (139.958). Projected Growth (PEG Ratio) (1.025) is also within normal values, averaging (0.786). UNH has a moderately high Dividend Yield (0.024) as compared to the industry average of (0.009). P/S Ratio (0.757) is also within normal values, averaging (0.569).
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating fairly steady price growth. UNH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 58 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UNH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of hospital and medical service plans
Industry ManagedHealthCare
Advertisement